Liver fibrosis and hepatic stellate cells improvement of chronic hepatitis c patients by interferon-beta-1 a with or without sustained viral response

Hepato-Gastroenterology

Volumn 56, Issue 90, 2009, Pages 328-334

  Rao, Hui Ying ^a   Wei, Lai ^a   Li, Jing ^a   Zhang, Lan Fang ^a   Chen, Huan Yong ^b   Zhu, Li Min ^c   Liu, Feng ^a   Sun, Yan ^a   Wang, Hao ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c Tianjin Infectious Disease Hospital   (China)

Author keywords

Chronic Hepatitis C; Interferon beta; Liver fibrosis; Treatment

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA1A INTERFERON; COLLAGEN TYPE 3; RIBAVIRIN;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; STELLATE CELL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOPSY; COLLAGEN; DRUG THERAPY, COMBINATION; FEMALE; HEPATIC STELLATE CELLS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-BETA; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LOGISTIC MODELS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RIBAVIRIN; TREATMENT OUTCOME;

EID: 67649216264     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Poynard T, Yuen MF, Ratziu V, et al: Viral hepatitis C. Lancet 2003;362:2095-2100.
2. Di Bisceglie AM: Natural history of hepatitis C: its impact on clinical management. Hepatology 2000; 31:1014-1018.
3. Hoofnagle JH: Course and outcome of hepatitis C. Hepatology 2002; 36 (Suppl 1):S21-S29.
4. Afdhal NH: The natural history of hepatitis C. Semin Liver Dis 2004;24(Suppl 2):3-8.
5. David E, Pucci A, Palladin D, et al: Histologic changes in liver biopsy specimens produced by recombinant inter-feron-alpha 2b therapy for chronic non-A, non-B viral hepatitis. Am J Clin Pathol 1992; 98:397-401.
6. Tsubota A, Kumada H, Chayama K, et al: Time course of histological changes in patients with a sustained biochemical and virological response to interferon-alpha ther-apy for chronic hepatitis C virus infection. J Hepatol 1997;27: 49-55.
7. Lee SS: Histological response to interferon alfa-based therapies in hepatitis C. Semin liver Dis 2004;24(Suppl 2):55-60.
8. Kaserer K, Fiedler R, Steindl P, et al: Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology 1998;32:454-461.
9. Hiramatsu N, Hayashi N, Kasahara A, et al: Improvement on liver fibrosis in chronic hepatitis C patients treated with natural interferon-alpha. J Hepatol 1995; 22:135-142.
10. Kim Al, Saab S: Treatment of hepatitis C. Am J Med 2005; 118:808-815.
11. Kaito M, Yasui-Kawamura N, Iwasa M, et al: Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C. Hepatogastroenterology 2003; 50:775-778.
12. Pellicano R, Palmas F, Cariti G, et al: Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2002; 14:1377-1382.
13. Sakaida I, Nagatomi A. Hironaka K, et al: Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy. Am J Gastroenterol 1999; 94:489-496.
14. Benyon RC, Arthur MJP: Mechanisms of hepatic fibrosis. J Pediatr Gastroenterol Nutr 1998; 27:75-85.
15. Bataller R, Brenner DA: Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21:437-451.
16. Reeves HL, Friedman SL: Activation of hepatic stellate cells-a key issue in liver fibrosis. Front Biosci 2002; 7:d808-826.
17. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002. Hepatology 2002; 36:3-20.
18. Strader DB, Wright T, Thomas DL, et al; American Association for the Study of Liver Diseases: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-1171.
19. Alberti A, Noventa F, Benvegnu L, et al: Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002; 137:961-964.
20. Ishak K, Baptista A, Bianchi L, et al: Histological grading and staging of chronic hepatitis. J Hepatology 1995; 22:696-699.
21. Knodell RG, Ishak KG, Black WC, et al: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431-435.
22. Schmit-Graff A, Kruger S, Bochard F, et al: Modula tion of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol 1991;138:1233-1242.
23. Thomas DL, Seeff LB: Natural history of hepatitis C. Clin Liver Dis 2005;9:383-398.
24. Reddy KR, Wright TL, Pockros PJ, et al: Efficacy and safety of pegylated (40kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33: 433-438.
25. Manns MP, McHutchison JG, Gordon SC, et al: Pegin-terferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
26. Fried MW, Shiffinan ML, Reddy KR, et al: Peginterfer on alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
27. Hadziyannis SJ, Sette H Jr, Morgan TR, et al: PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration andribavirin dose. Ann Intern Med 2004; 140:346-355.
28. Brok J, Gluud LL, Gluud C: Ribavirin plus interferon versus interferon for chronic hepatitis C. Cochrane Database Syst Rev 2005;20:CD005445.
29. Moreno-Otero R: Therapeutic modalities in hepatitis C: challenges and development. J Viral Hepat 2005; 12:10-19.
30. Heathcote EJ, Shiffman ML, Cooksley WG, et al: Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680.
31. Camma C, Di Bona D, Schepis F, et al: Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39:333-342.
32. Cornberg M, Hadem J, Herrmann E, et al: Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: A randomized open-label pilot study. J Hepatol 2006;44:291-301.
33. Caballero T, Perez-Milena A, Masseroli M, et al: liver fibrosis assessment with semiquantitative indexes and image analysis quantification in sustained-responder and non-responder interferon-treated patients with chronic hepatitis C. J Hepatol 2001;34:740-747.
34. Arima M, Terao H, Kashima K, et al: Regression of liver fibrosis in cases of chronic liver disease type C: quantitative evaluation by using computed image analysis. Intern Med 2004; 43:902-910.
35. Kryczka W, Chrapek M, Paluch K, et al: Progress of liver disease in chronic hepatitis C patients who failed antiviral therapy. Med Sci Monit 2003;9(Suppl 3):25-28.
36. De Torres M, Poynard T: Risk factors for liver fibrosis progression in patients with chronic hepatitis C. Ann Hepatol 2003;2:5-ll.
37. Wang X, Tang X, Gong X, et al: Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2. Gastroenterology 2004; 127:1174-88.
38. Rockey DC, Housset CN, Friedman SL: Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 1993;92:1795-1804.
39. Rockey DC, Boyles JK, Gabbiani G, et al: Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J Submicrosc Cytol Pathol 1992; 24:193-203.
40. Friedman SL: liver fibrosis-from bench to bedside. J Hepatol 2003;38(Suppl 1): S38-53.
41. Shibata N, Watanabe T, Okitsu T, et al: Establishment of an immortalized human hepatic stellate cell line to develop antifibrotic therapies. Cell Transplant 2003; 12:499-507.
42. Bedossa P, Paradis V: liver extracellular matrix in health and disease. J Pathol 2003; 200:504-515.
43. Guido M, Rugge M, Chemello L, et al: Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy. J Hepatol 1996; 24:301-307.
44. Shen H, Zhang M, Minuk GY, et al: Different effects of rat interferon alpha, beta and gamma on rat hepatic stellate cell. BMC Cell Biol 2002; 3:9-13.